AcquisitionOther

XOMA Corp acquired Kinnate Biopharma

Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.

Deal tape row

XOMA Corp -> Kinnate Biopharma · $2.3352

This acquisition will further add to our sizable cash balance that resulted from the VABYSMO transaction, as well as potentially add several programs to our royalty portfolio, stated Owen Hughes, Chief Executive Officer of XOMA.

Open source record (SEC) ↗